Bullfrog AI Holdings, Inc. Warrants - BFRGW STOCK NEWS

On April 6, 2023, BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) announced that CEO Vin Singh will appear on The RedChip Money Report on Bloomberg TV on April 8, 2023, at 7 p.m. ET. The broadcast reaches approximately 73 million homes in the U.S. Singh will discuss the company’s exclusive licensing agreement with Johns Hopkins’ Applied Physics Lab for its AI technology in drug development, the current development pipeline, and potential partnership opportunities.

BullFrog AI specializes in precision medicine using machine learning. Its proprietary bfLEAP™ platform aims to enhance drug development success by predicting patient responses, ultimately reducing development costs and improving patient outcomes.

BullFrog AI Holdings (Nasdaq: BFRG; BFRGW) has announced a worldwide license agreement with Johns Hopkins University Applied Physics Laboratory for patented technology to enhance its bfLEAP™ platform, which focuses on accelerating therapeutic development. This platform employs advanced analytics to improve the identification of relevant data, thereby potentially reducing development costs and failure rates for new therapeutics. The licensed technologies include Prometheus and Seagull, which enhance data analysis capabilities. BullFrog aims to use this technology to streamline drug development and improve patient outcomes.

BullFrog AI Holdings (NASDAQ: BFRG; BFRGW) has announced its listing on the Webull platform, connecting with over 1.3 million active investors. This collaboration aims to enhance communication with shareholders by providing real-time updates on corporate activities such as news, earnings, and presentations. Founder and CEO Vin Singh expressed excitement about the partnership, emphasizing the efficiency of digital communications for reaching investors. BullFrog AI focuses on precision medicine and AI-driven drug development, using its proprietary bfLEAP™ platform to optimize therapeutic outcomes and reduce costs in pharmaceutical development.

BullFrog AI Holdings (NASDAQ:BFRG; BFRGW) has announced a collaboration with the J. Craig Venter Institute to co-develop a synthetic HSV-1 virus targeting colorectal cancer. This partnership aims to utilize BullFrog's bfLEAP™ AI platform for optimizing cancer therapeutics with reduced toxicity while enhancing efficacy. With colorectal cancer being the third most prevalent cancer in the U.S., this project seeks to create a novel class of treatments, potentially revolutionizing precision medicine. The initiative emphasizes BullFrog's commitment to advancing drug development through AI innovation.

On February 16, 2023, Bullfrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) successfully completed its IPO, raising approximately $8.4 million by selling 1,297,318 units at $6.50 per unit. Each unit comprises one share of common stock and two types of warrants. The offering includes an underwriters' option to purchase additional shares, amounting to 15% of the units sold, within 45 days. This capital will support Bullfrog AI's mission to advance precision medicine through machine learning technologies. WallachBeth Capital and Kingswood served as the joint bookrunners for this offering.

Bullfrog AI Holdings (NASDAQ:BFRG; BFRGW) has successfully closed its initial public offering, securing approximately $8.4 million through the sale of 1,297,318 units priced at $6.50 each. Each unit includes one share of common stock and two warrants with exercise prices of $7.80 and $8.125. Trading for the shares and tradeable warrants commenced on February 14, 2023. The underwriters hold an option to purchase up to 15% additional shares within 45 days. Bullfrog AI focuses on using machine learning for precision medicine, partnering with major institutions like Johns Hopkins University to enhance drug development.

BullFrog AI Holdings (NASDAQ: BFRG; BFRGW) announced its participation in Benzinga's All Access event on February 17, 2023, at 11:00 a.m. ET. Vin Singh, CEO of BullFrog AI, will present and conduct a Q&A session, available via a live video webcast.

The company's platform leverages AI to enhance drug development and reduce clinical trial timelines. BullFrog AI collaborates with renowned research institutions to facilitate precision medicine, aiming to predict patient responses to therapies. This innovation is crucial for decreasing therapeutic development costs and increasing success rates.

WallachBeth Capital LLC announced the pricing of BullFrog AI Holdings' initial public offering (IPO) of 1,297,318 units at $6.50 per unit, raising approximately $8.4 million before expenses. The IPO is expected to close around February 16, 2023. Each unit includes one share of common stock, a tradeable warrant with an exercise price of $7.80, and a non-tradeable warrant priced at $8.125. The shares and warrants are slated to begin trading on Nasdaq under symbols BFRG and BFRGW on February 14, 2023. Underwriters have a 45-day option to purchase additional shares and warrants, totaling up to 15% of the offering.

Bullfrog AI Holdings (NASDAQ:BFRG; BFRGW) announced the pricing of its initial public offering (IPO) of 1,297,318 units at $6.50 per unit, generating approximately $8.4 million in gross proceeds. Each unit consists of one share of common stock and two types of warrants to purchase additional shares at specified prices. Trading of shares and tradeable warrants commenced on February 14, 2023, with the offering expected to close around February 16, 2023. The underwriters have a 45-day option to purchase additional shares and warrants, representing up to 15% of the units sold, subject to customary conditions.